ARA-290
Also known as: Cibinetide, ARA 290
Key Facts: ARA-290
- Category
- Cognitive
- FDA Status
- Not FDA Approved
- Clinical Status
- Phase II/III Clinical Trials - Orphan Drug Designation (US/EU)
- Administration
- Subcutaneous injection
- Typical Dose
- 4 mg daily
- Frequency
- Once daily
- Evidence Level
- Phase II/III Trials
- Duration
- 28-day courses in trials
What to Expect
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
Mechanism of Action
ARA-290 selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (β common receptor). This receptor is expressed on damaged and inflamed tissues. Activation triggers anti-apoptotic, anti-inflammatory, and tissue-protective pathways without stimulating red blood cell production.
Research Summary
Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals.
Dosing Information
Typical Dosingⓘ
Community experience
4 mg daily
4-8 mg daily
Once daily
Cibinetide. Clinical trial doses. Used for neuropathy and sarcoidosis. Non-erythropoietic EPO derivative.
Research Dosingⓘ
Scientific studies
Doses from clinical trial protocols
Doses from Studies
4 mg daily subcutaneous
Duration
28-day courses in trials
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Consistent daily timing
Once daily
Food Recommendation
With or without food
Why This Timing?
Clinical trials used once-daily dosing at consistent times
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated in trials
- ●Injection site reactions
- ●No erythropoietic effects (no blood thickening)
- ●Not FDA approved
References
Related Peptides
Peptides commonly compared with ARA-290 or used in similar applications.
GB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia and currently in clinical trials for anxiety and cognitive enhancement. Users report significant improvements in focus, attention, and ADHD-like symptoms.
CognitiveSelank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
CognitiveSemax
Clinical TrialsA synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
CognitiveCerebrolysin
Clinical TrialsA mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
CognitiveDihexa
PreclinicalA potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
CognitiveP21
PreclinicalA synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.
CognitiveWant updates on ARA-290 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.